Reviving Early Diagnosis of Cardiovascular Disease in the Utrecht Health Project

Status

Enrolling by invitation

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05775354

Acronym

RED-LRGP

Enrollment

1476

Registered

2023-03-20

Start date

2023-11-01

Completion date

2026-10-31

Last updated

2024-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Coronary Artery Disease, Heart Failure, Valvular Heart Disease

Keywords

early diagnosis, cardiovascular diseases, cohort study, primary health care

Brief summary

The goal of this randomized trial is to compare the diagnostic yield of a screen-like early diagnosis strategy to usual primary care to detect coronary artery disease (CAD), atrial fibrillation (AF), heart failure (HF), and/or valvular heart disease (VHD) in community people aged 50-80 years who participate in the Utrecht Health Project. The diagnosis strategy consists of a questionnaire with questions related to symptoms suggestive of CAD, AF or HF, a focused physical examination, laboratory testing, electrocardiography, and echocardiography.

Interventions

DIAGNOSTIC_TESTEarly diagnosis strategy

RED-CVD early diagnosis questionnaire, physical examination, laboratory testing, electrocardiography, echocardiography

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

50 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Aged 50-80 years * Being a participant of LRGP * Having indicated in the LRGP informed consent to be interested in participating in further research.

Exclusion criteria

* Diagnosed with coronary artery disease and atrial fibrillation and heart failure. * Undergoing major (cardiovascular) surgery, and/or revascularisation therapy and/or transplantation treatment within 3 months after enrolment. * Not willing to give written informed consent for RED-LRGP. * Not allowing incidental findings to be reported to him/herself or their own GP.

Design outcomes

Primary

Measure	Time frame
Coronary artery disease	1 year
Atrial fibrillation	1 year
Heart failure	1 year
Valvular heart disease	1 year

Secondary

Measure	Time frame
Echocardiographic abnormalities	1 year
Costs	1 year
Health-related quality of life	1 year
CVD family history and women's reproductive history	1 year
Cardiovascular risk profile	1 year

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026